MXPA05010171A - Agonistas de receptor muscarinico m1 para manejo del dolor. - Google Patents

Agonistas de receptor muscarinico m1 para manejo del dolor.

Info

Publication number
MXPA05010171A
MXPA05010171A MXPA05010171A MXPA05010171A MXPA05010171A MX PA05010171 A MXPA05010171 A MX PA05010171A MX PA05010171 A MXPA05010171 A MX PA05010171A MX PA05010171 A MXPA05010171 A MX PA05010171A MX PA05010171 A MXPA05010171 A MX PA05010171A
Authority
MX
Mexico
Prior art keywords
compound
optionally substituted
muscarinic
neuropathic pain
subject
Prior art date
Application number
MXPA05010171A
Other languages
English (en)
Spanish (es)
Inventor
Rodriguez Mario
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of MXPA05010171A publication Critical patent/MXPA05010171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MXPA05010171A 2003-03-28 2004-03-26 Agonistas de receptor muscarinico m1 para manejo del dolor. MXPA05010171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45904503P 2003-03-28 2003-03-28
PCT/US2004/009339 WO2004087158A2 (en) 2003-03-28 2004-03-26 Muscarinic m1 receptor agonists for pain management

Publications (1)

Publication Number Publication Date
MXPA05010171A true MXPA05010171A (es) 2005-12-12

Family

ID=33131858

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010171A MXPA05010171A (es) 2003-03-28 2004-03-26 Agonistas de receptor muscarinico m1 para manejo del dolor.

Country Status (13)

Country Link
US (1) US20050130961A1 (enExample)
EP (1) EP1613321A2 (enExample)
JP (1) JP2006521399A (enExample)
KR (1) KR20050112116A (enExample)
CN (1) CN1777425A (enExample)
AU (1) AU2004226430A1 (enExample)
BR (1) BRPI0409523A (enExample)
CA (1) CA2520125A1 (enExample)
MX (1) MXPA05010171A (enExample)
NZ (1) NZ542690A (enExample)
RU (1) RU2358735C2 (enExample)
WO (1) WO2004087158A2 (enExample)
ZA (1) ZA200508733B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
NZ533566A (en) * 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
WO2006008260A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric piperidine derivatives
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
DK2244737T3 (da) 2008-01-22 2019-07-08 Univ Texas Flygtige anæstetiske sammensætninger omfattende ekstraktionsopløsningsmidler til regional anæstesi og/eller smertelindring
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
KR20150143439A (ko) * 2013-03-15 2015-12-23 알레간 인코포레이티드 무스카린성 효능제
BR112016024472B1 (pt) 2014-04-23 2023-02-14 Takeda Pharmaceutical Company Limited Composto, medicamento, e, uso de um composto
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
WO2017069173A1 (ja) 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CA3131128A1 (en) * 2019-02-22 2020-08-27 Karuna Therapeutics, Inc. Compounds and methods of deuterated xanomeline for treating neurological disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000030632A1 (en) * 1998-11-23 2000-06-02 Eisai Co., Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
CN101016296A (zh) * 2000-04-28 2007-08-15 阿卡蒂亚药品公司 毒蕈碱性激动剂
WO2003028650A2 (en) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
NZ533566A (en) * 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists

Also Published As

Publication number Publication date
WO2004087158A2 (en) 2004-10-14
NZ542690A (en) 2009-04-30
WO2004087158A3 (en) 2005-03-31
ZA200508733B (en) 2006-09-27
RU2005133197A (ru) 2006-04-27
BRPI0409523A (pt) 2006-04-18
KR20050112116A (ko) 2005-11-29
AU2004226430A1 (en) 2004-10-14
US20050130961A1 (en) 2005-06-16
CA2520125A1 (en) 2004-10-14
JP2006521399A (ja) 2006-09-21
EP1613321A2 (en) 2006-01-11
RU2358735C2 (ru) 2009-06-20
CN1777425A (zh) 2006-05-24

Similar Documents

Publication Publication Date Title
MXPA05010171A (es) Agonistas de receptor muscarinico m1 para manejo del dolor.
EP1272218B1 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
US20020173505A1 (en) Medicament
JP5666910B2 (ja) 認知機能障害を治療するためのキット、組成物、製品もしくは医薬
US20210077487A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
CA2845039A1 (en) Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
JP2019516707A (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
JP4867123B2 (ja) 神経因性疼痛治療剤および神経因性疼痛のモデル動物
AU2009264016B2 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
RU2746871C2 (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
Chen et al. Ifenprodil for prolonged spinal blockades of motor function and nociception in rats
JP2000309545A (ja) 愛玩動物の年齢関連行動障害治療方法および治療用組成物
US20050228019A1 (en) Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
ES2664749T3 (es) Sal (l)-(+)-tartrato de (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propan-1-ona, su método de producción y uso
KR19990036248A (ko) 마약성 진통제의 의존·내성 형성 억제제
US20230165852A1 (en) Method for treating central nervous system disorders using dopamine d3 partial agonists
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
KR20230125804A (ko) 알츠하이머병의 치료를 위한 마시티닙
JP5441052B2 (ja) アルツハイマー病治療薬
PT1610785E (pt) Combinação farmacêutica para o tratamento de espasticidade e/ou dor.
JP2019509321A (ja) 疼痛を処置するための組み合わせ
CZ2003234A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty jako léčivo
EP0659409A2 (en) Substance 1 antagonists for the inhibition of angiogenesis